Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • 4DMedical Secures U.S. Deal with Intermountain Health, Unlocking Growth Path
    4DMedical Secures U.S. Deal with Intermountain Health, Unlocking Growth Path
    • News

  • Race Oncology Doses First Patient in RC220 Trial, Advancing Tumour Program
    Race Oncology Doses First Patient in RC220 Trial, Advancing Tumour Program
    • News

  • March 2025 quarter CPI above expectations – but RBA cut still likely
    March 2025 quarter CPI above expectations – but RBA cut still likely
    • News

  • Harris Technology to expand refurbished tech division amid rising demand from cost-conscious Australians
    Harris Technology to expand refurbished tech division amid rising demand from cost-conscious Australians
    • News

  • PYC Therapeutics Moves Toward First Treatment for Blinding Childhood Eye Disease
    PYC Therapeutics Moves Toward First Treatment for Blinding Childhood Eye Disease
    • News

  • Impact Minerals Accelerates HPA Market Entry with Strategic HiPurA® Acquisition
    Impact Minerals Accelerates HPA Market Entry with Strategic HiPurA® Acquisition
    • News

  • Equity Story Acquires Baker Young to Accelerate Retail Stockbroking Expansion
    Equity Story Acquires Baker Young to Accelerate Retail Stockbroking Expansion
    • News

  • Condor Confirms 3 Billion Barrel Oil Potential in Tumbes Basin
    Condor Confirms 3 Billion Barrel Oil Potential in Tumbes Basin
    • News

  • Atomo Scales Up HIV Self-Testing Through National Vending Machine Rollout
    Atomo Scales Up HIV Self-Testing Through National Vending Machine Rollout
    • News

  • Spenda Secures $3M Term Loan to Accelerate Growth
    Spenda Secures $3M Term Loan to Accelerate Growth
    • News

ECS ditches new cartridges to enter vapes and pastilles market

  • In News
  • November 13, 2023
  • Alinda Gupta
ECS ditches new cartridges to enter vapes and pastilles market

As of early 2023, over three million Aussies aged 14 and above were found to either smoke or vape. With a greater number of teens and young Aussies taking up vaping, it has created a massive potential market for cannabis cultivators and manufacturers like ECS Botanics (ASX: ECS).

ECS is launching a range of GMP-certified cannabidiol (CBD) and tetrahydrocannabinol (THC) pastilles and THC vapes. The pastilles (sweet medicinal pills) are available in both CBD and THC forms and combinations of both. The white-label pastilles range is sugar-free, plant-based, and available in various flavours and colours. Pastilles are chewed and dissolved in the mouth, allowing active ingredients to enter the bloodstream rapidly.

ECS is also launching a white-label THC distillate vape infused with additional terpenes (chemical compounds responsible for flavour, colour and aroma). Made in Australia, the vape cartridges use oil concentrates derived from ECS’ pharmaceutical-grade extracts. These extracts, in turn, are issued from the Company’s Australian-grown flower, packaged in child-resistant packaging. 

The cartridges will be available in 0.5 and 1 mL, and this new THC distillate vape infused with additional terpenes replaces the previous dried flower vaporiser cartridge product that ECS was going to introduce to the market in 2023.

ECS Managing Director, Nan-Maree Schoerie commented, “The expansion of our B2B product range to include GMP-certified CBD and THC pastilles and THC vapes provides our customers and their patients with alternative dosage methods. These products are manufactured under stringent pharmaceutical-grade GMP standards that meet all TGA quality and compliance requirements to manufacture pharmaceutical-grade cannabinoid products.”

The Company also noted that given its “improved performance in financial year 2023”, it will be boosting the base remuneration of Managing Director Nan-Maree Schoerie to $315,500, exclusive of superannuation, up from the previous $298,759.

In FY23, ECS reported a record revenue of $15.6 million, up 117% on FY22. Its EBITDA grew 10% to $1.6 million. It produced 50% more cannabis, allowing for the launch of new products and R&D. Come Q1 FY24, it witnessed a positive net operating cash flow, delivering a cash flow of $280k, with customer receipts growing 58% on Q1 FY23 to $4 million. 

As demand for its medical cannabis oils grows, Schoerie feels that ECS will have more avenues for profits.

Schoerie added, “Pastilles and vapes are relatively new delivery methods in the Australian market and will provide local patients with advanced treatment options. These innovative product ranges complement our existing B2B offering, leveraging our expertise to meet growing consumer demand for premium medicinal cannabis solutions. We have already received pre-orders for these new products and expect demand to increase rapidly.”

ECS’s products are expected to be in the market before the end of this quarter and will increase the ECS Botanics white-label offering to a range of four products: flowers, oils, pastilles and vapes. 

The Company ended Q1 FY24 with $2.5 million in cash.

  • About
  • Latest Posts
Alinda Gupta
Alinda is a Business Reporter for The Sentiment
Latest posts by Alinda Gupta (see all)
  • Ovanti’s iSentric signs contracts worth $14.4m with Malaysian commercial bank - June 27, 2024
  • Baby Bunting fights back from retail downturn with 5-year strategy, includes Gen-Z focus and self-funded growth - June 27, 2024
  • CLEO meets with US FDA to develop strategy for ovarian cancer test launch - June 26, 2024
  •  
  •  
  •  
  •  
  • asx ecs
  • cannabidiol
  • cannabis
  • CBD
  • ECS Botanics
  • Nan-Maree Schoerie
  • THC
  • vapes
  • vaping
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Alinda Gupta
Alinda is a Business Reporter for The Sentiment
Latest posts by Alinda Gupta (see all)
  • Ovanti’s iSentric signs contracts worth $14.4m with Malaysian commercial bank - June 27, 2024
  • Baby Bunting fights back from retail downturn with 5-year strategy, includes Gen-Z focus and self-funded growth - June 27, 2024
  • CLEO meets with US FDA to develop strategy for ovarian cancer test launch - June 26, 2024

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Alinda Gupta
Alinda is a Business Reporter for The Sentiment
Latest posts by Alinda Gupta (see all)
  • Ovanti’s iSentric signs contracts worth $14.4m with Malaysian commercial bank - June 27, 2024
  • Baby Bunting fights back from retail downturn with 5-year strategy, includes Gen-Z focus and self-funded growth - June 27, 2024
  • CLEO meets with US FDA to develop strategy for ovarian cancer test launch - June 26, 2024
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.